Technology

Kare Schultz

Giving Allergy Sufferers Options

Years of price hikes made pharma company Mylan’s anaphylaxis-­reversing EpiPen the poster child of unjust drug pricing, at $608 for a two-pack. But without a generic competitor, consumers were stuck. Enter Teva Pharmaceutical CEO Schultz. In August, Teva won FDA approval for what the agency called the first generic version of the EpiPen. There’s no price or market date yet, but the approval is already a win for patient choice. —Jamie Ducharme